Proteases and their inhibitors as prognostic factors for high-grade serous ovarian cancer

Ovarian carcinoma is one of the most lethal malignancies, but only very few prognostic biomarkers are known. The degradome, comprising proteases, protease non-proteolytic homologues and inhibitors, have been involved in the prognosis of many cancer types, including ovarian carcinoma. The prognostic significance of the whole degradome family has not been specifically studied in high-grade serous ovarian cancer. A targeted DNA microarray known as the CLIP-CHIP microarray was used to identify potential prognostic factors in ten high-grade serous ovarian cancer women who had early recurrence (<1.6 years) or late/no recurrence after first line surgery and chemotherapy. In women with early recurrence, we identified seven upregulated genes (TMPRSS4, MASP1/3, SPC18, PSMB1, IGFBP2, CFI – encoding Complement Factor I – and MMP9) and one down-regulated gene (ADAM-10). Using immunohistochemistry, we evaluated the prognostic effect of these 8 candidate genes in an independent cohort of 112 high-grade serous ovarian cancer women. Outcomes were progression, defined according to CA-125 criteria, and death. Multivariate Cox proportional hazard regression models were done to estimate the associations between each protein and each outcome. High ADAM-10 expression (intensity of 2–3) was associated with a lower risk of progression (adjusted hazard ratio (HR): 0.51; 95% confidence interval (CI): 0.29-0.87). High complement factor I expression (intensity 2–3) was associated with a higher risk of progression (adjusted HR: 2.30, 95% CI: 1.17–4.53) and death (adjusted HR: 3.42; 95% CI: 1.72–6.79). Overall, we identified the prognostic value of two proteases, ADAM-10 and complement factor I, for high-grade serous ovarian cancer which could have clinical significance.     

Hiperplasia endotelial papilar intravascular (tumor Masson) de localización ginecológica

Intravascular papillary endothelial hyperplasia or Masson's tumour is a non-neoplastic vascular lesion of reactive character. It is a rare diagnosis, clinically non-specific and with diverse locations. It is essential to take it into consideration and make a differential diagnosis with malignant vascular tumours such as angiosarcoma. Pathological study is fundamental for diagnosis. Treatment consists of complete resection of the tumour, including sufficiently wide margins to avoid recurrence.The case reported is an exceptional event, because of the pelvic location of the Masson's tumour that was diagnosed as part of the surgical staging of an ovarian cancer.     

Systematic review of acceptability,cardiovascular, neurological,bone health and HRT outcomes following risk reducing surgery in BRCA carriers

Primary surgical prevention in the form of risk-reducing salpingo-oophorectomy (RRSO) is the most effective option and the gold standard for ovarian cancer (OC) risk-reduction, particularly given the absence of an effective national OC screening programme. However, premenopausal RRSO leads to premature surgical menopause with detrimental long-term health sequelae particularly in women who do not/are unable to take hormone replacement therapy (HRT). HRT uptake in women undergoing pre-menopausal oophorectomy appears low and is dependent on informed counselling, the safety of HRT and efficacy in mitigating the health sequelae of premature menopause. Acceptance of a central role for the fallopian tube in OC etiopathogenesis, coupled with the detrimental consequences of premature menopause, has led to the attractive proposal of early-salpingectomy with delayed oophorectomy as an alternative OC surgical prevention strategy in premenopausal women who have completed childbearing but decline or wish to delay RRSO. The successful implementation of risk reducing surgery for OC prevention depends on the acceptability of surgery to both, recipients (e.g. BRCA1/BRCA2 carriers) and intervention deliverers (healthcare professionals/researchers). Acceptability is also informed by an understanding of health outcomes following risk reducing surgery and the safety of HRT. It is therefore vital to understand the effects of surgery on important health outcomes such as cardiovascular health, neurological function and bone health. We present a comprehensive review of acceptability, the selected health outcomes mentioned above and HRT safety following risk reducing surgery.     

31例卵巢恶性畸胎瘤临床分析

本文报道了我院收治的卵巢恶性畸胎瘤３１例，随访中２例失访，随访率为９３．５３％。并讨论了卵巢恶性畸瘤的治疗方式为手术加联合化疗，对年轻的Ｉ期患者可行患侧单侧附件切除术，术后化疗极为重要。化疗方法采用ＶＡＣ或ＰＶＢ方案联合化疗，本文还 影响预后的重要因素为临床分期期和病理学特点．     

雌二醇周效贴片166例疗效观察

本研究观察国产雌二醇周效贴片（Ｅ２贴片）治疗因卵巢功能低落所致的主要临床表现的疗效，结合血ＦＳＨ、ＬＨ、Ｅ２测定，阴道脱落细胞成熟指数和部分病例的子宫内膜活检，对Ｅ２贴片的疗效进行了综合评价。结果显示，雌二醇周效贴片对卵巢功能低落所致的潮热、出汗、失眠、情绪波动，眩晕和阴道干涩等有显著疗效，且疗效随用药时间的延长而递增，在用药１４０天时总有效率分别达９８．９％，９２．０％、９１．４％、９０．０％和７８．０％，对ＬＨ、ＦＳＨ的释放有抑制作用；血清Ｅ２水平属轻度升高，但趋于平稳；部分病例子宫内膜组织学检查未见雌激素作用所致的内膜增殖效应。用药期间部分病例出现周期性阴道出血，这对年轻卵巢功能早哀者在生理和心理上均有治疗意义，但对更年期患者会造成不便和不安感。约２０％的病例贴片局部有轻微痒感，无其它不良反应。     

卵巢恶性肿瘤与血小板增多关系分析

目的探讨卵巢恶性肿瘤伴发血小板增多的临床规律。方法回顾分析98例卵巢恶性肿瘤患者的临床资料,26例合并血小板增多。结果血小板增多占26.5%,其中晚期(Ⅲ+Ⅳ期)占88.46%,晚期患者血小板偏高明显增多,且肿瘤切除后血小板下降。结论卵巢恶性肿瘤伴发血小板增多晚期患者多见,预后差,血小板增多可作为判断卵巢肿瘤恶性程度及术后随访的指标。     

评估控制性卵巢刺激中预测卵巢反应性的指标

在辅助生育技术的实施中,控制性卵巢刺激(COS)方案是根据患者情况确定的,在用药剂量和启动时间的掌握上非常重要。由于卵巢本身反应性或基础状态的不同,不同年龄及不同病因的患者有着极大的差异,用量适当可避免因启动剂量过大造成卵巢过度剌激(OHSS),或剂量过少造成低反应,卵泡     

荷人卵巢癌严重联合免疫缺陷鼠腹腔移植模型的建立

目的 :建立荷人卵巢癌细胞株 SKOV3严重联合免疫缺陷小鼠 (SCID)动物模型。方法 :SCID鼠腹腔注射人 SKOV3卵巢癌细胞 1× 10 7个 /只 ,饲养在无特定病原体环境中 ,观察其生物学特性。结果 :实验组 3只 SCID小鼠腹腔内均见肿瘤生长 ,并形成以横膈、肠系膜、肝周、腹膜为主的转移灶 ,其中 1只肺部有镜下转移灶。移植后肿瘤细胞在形态、生长、分泌 CA12 5功能方面均与原细胞株保持一致。结论 :建立的荷人 SKOV3卵巢癌 SCID鼠腹腔移植模型能较好地模拟人卵巢癌腹腔播散的生物学特征。     

腹腔镜卵巢穿刺内凝治疗多囊卵巢不孕症的临床研究

目的探讨腹腔镜卵巢穿刺内凝对多囊卵巢不孕症的治疗价值。方法１５１例腹腔镜卵巢穿刺内凝术（实验组）和１５１例开腹卵巢楔切术（对照组）治疗多囊卵巢不孕症配对对比研究。结果实验组的手术时间３３．１±７．２ｍｉｎ，术中失血１５．６±４．７ｍｌ，总排卵率９２．０５％，总妊娠率４９．６７％，均优于对照组（Ｐ＜０．０１）；术后雄激素、ＬＨ／ＦＳＨ下降幅度小于对照组（Ｐ＜０．０１）。随时间推移，两组术后排卵巢、妊娠率均有下降倾向，而术后雄激素、ＬＨ／ＦＳＨ则有逐渐回升的倾向。结论腹腔镜卵巢穿刺内凝术对多囊卵巢不孕症有较好的治疗效果     

尿毒症患者的性激素变化及其临床意义探讨

目的 :探讨女性尿毒症患者卵巢功能障碍的发病情况及其临床意义。方法 :应用酶免疫法 (EIA)测定了2 3例更年期前女性尿毒症非透析患者、15例透析患者及 2 9例健康献血者中促卵泡素 (FSH)、泌乳素 (PRL)、促黄体素 (LH)、雌二醇 (E2 )及孕酮 (P)的水平。结果 :尿毒症女患者PRL、FSH及LH均较健康对照组升高 ,而孕酮值显著降低 ,对此均有显著差异 ;且尿毒症女患者PRL升高、孕酮值降低与肾小球滤过率 (GFR)呈明显相关。透析患者较非透析患者PRL升高更为明显 ,孕酮值亦较非透析患者有所升高 ,但无显著意义。结论 :尿毒症女患者的排卵障碍及月经紊乱等都与尿毒症的严重程度相平行。透析并不能改善尿毒症女患者的卵巢功能障碍 ,只有纠正与改善肾功能 ,才能使尿毒症女患者的卵巢功能得以改善